Dimensional Fund Advisors
ENGN icon

Dimensional Fund Advisors’s enGene Therapeutics ENGN Stock Holding History

Dimensional Fund Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$76.6K Hold
38,291
– – ﹤0.01% 3161
2026
Q2 		$66.2K Buy
38,291
+1,418
+4% +$5.78K ﹤0.01% 3175
2026
Q1 		$251K Buy
+36,873
New +$328K ﹤0.01% 3038

Other funds holding ENGN

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Indivisible Partners
Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return
Covestor
Covestor London, United Kingdom $157M AUM 35.87% 1-Year Est. Return
Fountainhead AM
Fountainhead AM Warren, New Jersey $143M AUM 21.75% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

Dimensional Fund Advisors's ENGN Position: Q3 2026 in Review

Dimensional Fund Advisors held its enGene Therapeutics (ENGN) position steady in Q3 2026 at 38,291 shares worth $76.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3161.

Dimensional Fund Advisors first reported a position in ENGN in Q1 2026 and has held it in 3 quarters since. The position peaked at $251K in Q1 2026. 13 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

  • Dimensional Fund Advisors held 38,291 shares of enGene Therapeutics worth $76.6K as of Q3 2026.
  • Dimensional Fund Advisors left its enGene Therapeutics share count unchanged in Q3 2026.
  • enGene Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #3161 holding.
  • Dimensional Fund Advisors first reported a position in enGene Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Dimensional Fund Advisors's enGene Therapeutics position peaked at $251K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.